Understanding Mesothelioma: The Impact of BAP1 and p16 in Accurate Diagnosis

Understanding Mesothelioma: The Impact of BAP1 and p16 in Accurate Diagnosis

Mesothelioma is a rare and serious type of cancer that affects the lining of organs like the lungs and abdomen. It is caused by exposure to a harmful substance called asbestos, which is sometimes used in construction materials.

Detecting mesothelioma can be tricky, and doctors often need special tests to be sure. A recent study looked into two important factors, called BAP1 and p16, to help diagnose mesothelioma more accurately.

Redefining Mesothelioma Diagnosis

Between 2019 and 2022, scientists studied 21 fluid samples from around the lungs and abdomen of people suspected to have mesothelioma. These samples were examined closely to find out if the BAP1 protein was missing and if the p16 gene had certain changes. These tests were important because they could provide important clues for an early diagnosis.

The people in the study were between 34 and 90 years old, with an average age of about 63 years. Out of the cases, 3 out of every 4 were female. Most of the mesothelioma cases were found in the lining around the lungs. Some had a type called epithelioid, while others had biphasic or sarcomatoid forms.

The BAP1 protein was missing in 11 out of 16 cases with mesothelioma in the lungs. When it came to the p16 gene, changes were seen in 11 out of 19 cases. Some cases had more changes than others, with a few having changes in almost all the cells examined. Interestingly, the changes in the p16 gene were only found in certain types of mesothelioma.

Early Mesothelioma Detection

This study provides important information for doctors trying to diagnose mesothelioma. If someone has been exposed to asbestos or shows signs of abnormal cells in fluid samples, it can be a strong hint that mesothelioma might be the cause. The BAP1 test can be a crucial first step in confirming the diagnosis, especially in tricky cases.

While the p16 gene test has some challenges, it can still be helpful in specific situations. This research brings us a step closer to better understanding and diagnosing mesothelioma, which is crucial for giving patients the best possible care.

Source

Aydogdu G, Özekinci S. Contribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology. Eur Rev Med Pharmacol Sci. 2023;27(20):10001-10007. doi:10.26355/eurrev_202310_34180. https://pubmed.ncbi.nlm.nih.gov/37916370/

Similar Posts

  • |

    Mesothelioma Blood Test May Be Possible

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

  • | |

    Needle Biopsy “Simple, Safe & Accurate” for Mesothelioma

    Mesothelioma researchers in China say a biopsy method that involves a single skin puncture can produce good diagnostic results for mesothelioma patients with little pain or risk. The study focused on percutaneous (through the skin) biopsy in patients who had unexplained fluid buildup or swelling in their abdomens. Abdominal distension and fluid buildup (called ascites) can be signs of peritoneal mesothelioma, a rare but aggressive cancer of the abdominal lining caused by exposure to asbestos. Peritoneal mesothelioma accounts for less than 30% of all mesothelioma cases. Because the symptoms may be vague and often develop many decades after asbestos exposure, peritoneal mesothelioma can be especially challenging to diagnose.  Misdiagnosis and under-diagnosis are not uncommon. In the newest study on percutaneous…

  • | |

    Inflammation Both “Friend and Foe” in Mesothelioma

    An immune system response that causes mesothelioma symptoms such as fever, fatigue, and weight loss may also be helpful to clinicians as a way to find and treat the disease. Scientists with The Asbestos Diseases Research Institute in Sydney, Australia make that case that both systemic inflammation (throughout the body) and at the site of a tumor – has long been associated with mesothelioma and other cancers. Inflammation results when the body attempts to address the imbalances of cancer by producing more of certain immune system cells. Some inflammatory markers, such as CD+8 T-cells and C-reactive protein, have been linked to better prognosis in mesothelioma. Other inflammatory markers, such as certain macrophages and a high neutrophil-to-lymphocyte ratio, can signal the…

  • | |

    FDG PET-CT Results Could Lead to Improved Mesothelioma Treatment

    In a recent study, researchers say a better understanding of certain diagnostic criteria could result in more targeted treatments for malignant mesothelioma. In a recent published report, doctors from the medical school at Dicle University in Diyarbakir, Turkey measured the relationship between PET-CT scan results and survival in 177 patients with malignant pleural mesothelioma. The patients were diagnosed between April 2007 and April 2011. They had a mean age of 55.4 and most (56%) were male. Patients in the study all had FDG PET-CT scans before beginning their mesothelioma treatment. FDG PET-CT scanning is a powerful imaging tool for mesothelioma and other cancers that combines a radioactive tracer with a combination of positron emission tomography and computed tomography scanning.  Because…

  • | |

    Mesothelioma Surgeons Report New Biopsy Technique

    A team of surgeons in Maryland have demonstrated how using a standard biopsy tool in a new way could improve the biopsy process for certain mesothelioma patients. An aggressive cancer of the pleural lining around the lungs, malignant pleural mesothelioma usually requires a tissue biopsy to make a definitive diagnosis. Often this is done using a rigid tool called a thoracoscope inserted into the chest wall while the patient is under general anesthesia. However, mesothelioma doctors at Walter Reed National Military Medical Center detail the case of a 79-year-old suspected mesothelioma patient whose biopsy was done in a minimally-invasive way, under conscious sedation, thanks to the novel use of a standard tool. Although the patient had several of the common signs…

  • |

    New Serum Marker Could Improve Mesothelioma Diagnosis

    Japanese researchers believe they have found a way to diagnose a rare form of mesothelioma earlier using a simple blood test. Diffuse malignant peritoneal mesothelioma (DMPM), which represents about a fourth of all mesothelioma cases, is an aggressive malignancy that spreads across the lining of the abdomen. In most cases, DMPM is lethal within a year. The standard treatment for diffuse malignant peritoneal mesothelioma is cytoreductive surgery to remove as much of the mesothelioma as possible, followed by intraperitoneal chemotherapy to destroy residual cancer cells. In some studies, this approach has resulted in 5-year survival rates of 30 to 60 percent. However, it is most successful when it is performed early, while the primary mesothelioma tumor is more easily removed. Like all forms of…